Management of Refractory Constipation with Prokinetics

Introduction to Prokinetic Therapy

The National Comprehensive Cancer Network recommends metoclopramide as a third-line agent for refractory constipation when gastroparesis or severe upper GI dysmotility is suspected, after stimulant laxatives and osmotic laxatives have failed 1, 2

Metoclopramide has limited efficacy for isolated constipation because it primarily affects the upper GI tract, increasing gastric and duodenal motility, but has little to no effect on the motility of the colon, according to the American Gastroenterological Association 1, 3

The American College of Gastroenterology recommends using metoclopramide 10-20 mg orally 3-4 times daily when gastroparesis is documented or strongly suspected as contributing to constipation, or when upper GI dysmotility symptoms accompany constipation 1, 3
The National Comprehensive Cancer Network specifically recommends considering metoclopramide if gastroparesis is suspected in the context of persistent constipation 2

The American Gastroenterological Association recommends bisacodyl 10-15 mg orally 2-3 times daily as a first-line approach for standard constipation without gastroparesis, targeting colonic motility directly 1, 2
Prucalopride, a 5-HT4 agonist, is superior for chronic constipation, directly stimulating colonic motility through selective serotonergic pathways, and is recommended by recent guidelines for hypermobile Ehlers-Danlos syndrome-related constipation 3

The National Comprehensive Cancer Network recommends a step-wise approach for refractory constipation, including ruling out impaction, excluding secondary causes, optimizing stimulant laxative use, adding osmotic laxatives, and considering metoclopramide only if gastroparesis is suspected 1, 2

The American College of Gastroenterology recommends against using metoclopramide for clozapine-induced constipation due to additive dopamine antagonism increasing extrapyramidal symptom risk 1, 2
Metoclopramide has dual utility in cancer/palliative care populations for both nausea and constipation when gastroparesis contributes to symptom burden, but remains a second-line agent after standard laxative escalation 1, 2

The National Comprehensive Cancer Network recommends adding bisacodyl 10-15 mg orally 2-3 times daily as the next step for patients with refractory constipation, with a goal of one non-forced bowel movement every 1-2 days 4, 5, 6
Before adding bisacodyl, it is essential to rule out fecal impaction, which can be done through digital rectal exam or imaging, and if present, treated with glycerin suppositories, bisacodyl suppositories, or manual disimpaction 4, 5, 6

The American College of Cardiology suggests considering metoclopramide 10-20 mg every 6-8 hours if gastroparesis or severe dysmotility is suspected, to address the motility component that osmotic laxatives alone cannot fix 4, 7

The National Comprehensive Cancer Network advises ruling out secondary causes of constipation, including metabolic causes (hypercalcemia, hypokalemia, hypothyroidism, diabetes mellitus), mechanical obstruction, and medication-induced constipation, before escalating therapy further 4, 5, 6

The National Comprehensive Cancer Network recommends performing a rectal exam to assess for impaction, and if impacted, disimpacting first (suppository or manual), then starting maintenance, and if not impacted, adding bisacodyl 10-15 mg orally 2-3 times daily to the current regimen 4, 5, 6